QVAR REDIHALER
Peakbeclomethasone dipropionate hfa
NDAINHALATIONAEROSOL, METERED
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QVAR REDIHALER is a metered-dose inhaler containing beclomethasone dipropionate HFA, a corticosteroid indicated for asthma management via inhalation. As a reformulated inhaler product, it delivers the active ingredient through an improved device mechanism compared to earlier formulations. The product treats persistent asthma by reducing airway inflammation and controlling symptoms. It represents a convenient, breath-actuated delivery option in the inhaled corticosteroid market.
$0.0BPart D
15.3 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QVAR REDIHALER supports roles including brand management, respiratory specialists, and field sales teams focused on asthma care. Key skills for this product include knowledge of inhaler device mechanics, asthma guideline positioning, and managed care/formulary strategy. Currently zero job openings are linked to this product, reflecting stable staffing levels typical of mature product portfolios.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.